Researchers from Mount Sinai School of Medicine in New York say they have identified a six-gene signature that can be used in a test to predict survival in men with aggressive prostate cancer.
Cxbladder Monitor testing found to reduce frequency of cystoscopy for patients with NMIBC
No CxM-negative patients had findings of a recurrent tumor on a follow-up cystoscopy.
Dr. Kishan highlights findings from the MIRAGE trial in prostate cancer
Amar Kishan, MD, highlights findings showing that MRI-guided SBRT is superior to CT-guided SBRT in localized prostate cancer.
The safety and oncologic benefits of transperineal vs transrectal MRI-guided prostate biopsy
"These studies, taken together, offer important insight into the direction we should be heading in prostate cancer diagnosis: toward a targeted-only TP biopsy," write Tarik Benidir, MD, and Zeyad Schwen, MD.
Speaking of Urology: ASCO GU 2023 Highlights
Laura Bukavina, MD, and Kyle Rose, MD, discuss some of the notable abstracts from the 2023 ASCO GU conference.
Minimizing incontinence after radical prostatectomy: Lessons learned
"I've worked in 3 different countries, I've seen dozens of people doing robotic radical prostatectomy...so my current practice is kind of a “best of” what I have seen and learned," says Ricardo Soares, MD.
Phase 3 ARASTEP study to investigate darolutamide plus ADT for hormone-sensitive prostate cancer
"With ARASTEP, we are optimistic about the potential to help patients at this earlier stage of [prostate cancer]," says Tara Frenkl, MD.
2 Clarke Drive Cranbury, NJ 08512